MGMolly E. Gallagher

Molly E. Gallagher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Molly E. Gallagher has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MicrobeRT: A Framework and Suite of Fine-tuned Language Models for Genomic Sequences

    by Vijay Narayan, Brian Merritt, Sanjeevani Choudhery, Daniel Jimenez, Stanley Ta, Daniel S Berman, Jeremy Ratcliff, Molly E Gallagher

    Accurate and reproducible metagenomic analysis is essential for effective infectious disease surveillance. Targeted diagnostics such as culturing, antigen assays, and multiplex PCR panels identify only predefined organisms and can fail to identify atypical or novel infections. Shotgun metagenomics offers hypothesis-free detection, but adoption is limited by workflow complexity, dependence on mutable reference databases, and high computational cost. To combat these challenges, we introduce MicrobeRT, an integrated suite of genomic language models fine-tuned to classify metagenomic sequencing reads across three tasks: (i) species level taxonomic identification, (ii) antibiotic resistance gene detection, and (iii) pathogenicity assessment. The framework builds on three pre-trained genomic language models - Nucleotide Transformer (Dalla-Torre et al 2025), DNABERT (Ji et al 2021, Zhou et al 2024), and HyenaDNA (Nguyen et al 2024) - leveraging their large-scale genomic pre-training, adaptability to downstream tasks, and, in the case of HyenaDNA, ability to capture long-range sequence dependencies. The models are fine-tuned on large, curated datasets spanning microbial, viral, fungal, and human genomes, including more than 500,000 genomes and 250,000 antibiotic resistance gene sequences. To evaluate the performance of our fine-tuned genomic language models across classification tasks, we developed a benchmarking framework that compares MicrobeRT against state-of-the-art (SOTA) bioinformatics tools. Across both simulated and empirical datasets, the models achieve strong performance while reducing computational overhead. MicrobeRT is released as open-source software, enabling further fine-tuning and reproducible integration of alternative models and classifiers. We also demonstrate seamless, drop-in integration by incorporating our fine-tuned taxonomic classification models as an optional add-on within the open-source TaxTriage pipeline (Merritt et al 2026). MicrobeRT demonstrates the feasibility of three clinically relevant multi-label analyses, offering a practical path to scalable, reproducible metagenomic diagnostics and enabling broader deployment of AI/ML-enhanced infectious disease testing.

  • Open Access

    A Simulation of Semi-Infectious Particles and Genome Complementation Reproduces Interferon Response by Respiratory Epithelial Cells in vitro during Influenza A Virus Infection

    by Pedro C Dal-Castel, Jessica D Resnick, James P Sluka, Molly E Gallagher, Mika Helfers, Ian M Bird, Jeremy D Ratcliff, Sarah L Grady, James A Glazier

    In the respiratory epithelium, interferon (IFN)-induced antiviral resistance acts as a defense against infection. Influenza A viruses (IAVs) have evolved multiple strategies to counteract these defenses, including expression of the viral protein NS1, which inhibits both IFN production and the IFN-mediated transcription of Interferon Stimulated Genes (ISG) in infected cells. However, experiments show that this inhibition is imperfect, especially at a low multiplicity of infection (MOI). One hypothesis to describe this phenomenon relies on the presence of Semi-infectious Particles (SIPs) that fail to express NS1. In this scenario, the IFN response is incompletely suppressed at low MOI, while it is successfully inhibited at high MOI because most cells are infected by multiple virions, allowing complementation to rescue NS1 expression. To test this hypothesis, we developed a computer simulation that models viral gene defects and complementation. We compared the model outputs with in vitro experiments at different MOIs. To assess inter-host reproducibility and calibrate the model parameters, we measured IFN levels and viral load over time in bronchial epithelial cell cultures from five human donors. We observed no statistically significant heterogeneity in IFN response or virus production between donors, and the calibrated simulation fits the experimental time series for IFN and viral load. Consistent with literature (1,2), the model predicted higher IFN levels at low MOI than at high MOI. Finally, simulations of IFN treatment applied before and during infection showed reduced viral load, in agreement with our experiments. Increasing the viral genome defect rate above the experimentally estimated rate increased IFN levels and reduced viral load. High MOI simulations showed lower cumulative IFN levels, while NS1 knockout recovered high IFN levels. These results demonstrate the ability of mechanistic models of viral dynamics to predict the innate immune response of epithelial cells during viral infection.

  • Open Access

    Influence of the Built Environment on Airflow, Contamination, and Infection in the Operating Room: A Systematic Literature Review

    by Shirley M. Klimkiewicz, Molly E. Gallagher, Anastasia S. Lambrou, Oluwaferanmi E. Adeyemo, Amy M. Andrelchik, Kavita Braun, Madeline B. Ford, Terrence J. Garcia, Stephanie Ku, Kaitlin Rainwater-Lovett, et al.

    Background Healthcare-associated infections (HAIs) constitute a significant financial strain on healthcare systems across the world, with surgical site infections (SSIs) being the costliest form. Despite the existence of diverse sources of infection in the operating room (OR), current literature focuses on human and procedural sources of contamination that could lead to an infection. Comparatively, the OR built environment is understudied as a potential disease transmission interface between the environment, patients, and surgical staff. This systematic literature review aims to investigate how the physical characteristics and components of the built environment impact airflow, infection risk, aerosols, particle counts, contamination, and pathogens in operating rooms. Methods and Findings Literature searches were conducted in the PubMed and Web of Science Core Collection databases on December 21, 2020, ultimately retrieving 2,965 articles after duplicates were removed. During abstract screening, all abstracts were independently reviewed by two authors and conflicts were resolved by a third author. All articles published since January 1, 2010, that reported primary data investigating an aspect of the built environment inside an OR in relation to airflow, contamination, and/or infection for which the full text in English was available were included. This resulted in the inclusion of 138 articles, which includes studies conducted in ORs during active surgeries, computer modeling studies, and simulations in which a real OR was used for a mock surgical procedure. Six major built environment categories were identified based on the collected literature: OR layout, disinfection systems, surgical lights, doors, ventilation, and portable airflow devices. A survey created on Qualtrics software was used to record the aspect of the built environment and the outcome of each study, as well as the relationship between the two. Conclusions While OR ventilation has been studied extensively, the OR built environment as a whole is understudied in relation to airflow, contamination, and infection. The current literature is inconsistent in both its findings and subsequent recommendations, making it difficult to inform hospital design in the context of SSIs. No articles were identified that discussed respiratory infection transmission in the OR, and very few addressed healthcare worker (HCW) safety in relation to the OR built environment. The significant discrepancies in the literature identified in this review highlight the need for future studies that assess the quality and bias of these studies before firm recommendations can be made. Future work should also focus on addressing the lack information regarding respiratory infection transmission in the OR, especially in the context of HCW safety.

  • Open Access

    Modeling the use of SARS-CoV-2 vaccination to safely relax non-pharmaceutical interventions

    by Alicia N.M. Kraay, Molly E. Gallagher, Yang Ge, Peichun Han, Julia M. Baker, Katia Koelle, Andreas Handel, Benjamin A Lopman

    In response to the COVID-19 pandemic, widespread non-pharmaceutical interventions (NPIs), including physical distancing, mask wearing, and enhanced hygiene, have been implemented. As of March 2021, three effective vaccines have been approved for emergency use in the United States, with several other vaccines in the pipeline. We use a transmission model to study when and how NPIs could be relaxed in the United States with relative safety as vaccination becomes more widespread. We compare different relaxation scenarios where NPIs begin to relax 0-9 months after vaccination begins for both a one dose and two dose strategy, with historical levels of social interactions being reached within 1 month to 1 year. In our model, vaccination can allow widespread relaxation of NPIs to begin safely within 2 to 9 months, greatly reducing deaths and peak health system burden compared to relaxing NPIs without vaccination. Vaccinated individuals can safely begin to relax NPIs sooner than unvaccinated individuals. The extent of delay needed to safely reopen depends primarily on the rate of vaccine rollout, with the degree of protection against asymptomatic infection playing a secondary role. If a vaccination rate of 3 million doses/day can be achieved, similar to the typical rollout speed of seasonal influenza vaccination, NPIs could begin to be safely relaxed in 2-3 months. With a vaccination rate of 1 million doses/day, a 6–9-month delay is needed. A one dose strategy is preferred if relative efficacy is similar to a two-dose series, but the relative benefit of this strategy is minimal when vaccine rollout is fast. Due to the urgent need to pursue strategies that enable safe relaxation of NPIs, we recommend a two-dose strategy with an initial delay of at least 3 months in relaxing restrictions further, and that the speed of vaccine rollout be given immediate priority.


  • Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates

    by Molly E. Gallagher, Andrew J. Sieben, Kristin N. Nelson, Alicia N. M. Kraay, Walter A. Orenstein, Ben Lopman, Andreas Handel, Katia Koelle


  • Open Access

    Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates

    by Molly E. Gallagher, Andrew J. Sieben, Kristin N. Nelson, Alicia N. M. Kraay, Ben Lopman, Andreas Handel, Katia Koelle

    Significant progress has already been made in development and testing of SARS-CoV-2 vaccines, and Phase III clinical trials have begun for 6 novel vaccine candidates to date. These Phase III trials seek to demonstrate direct benefits of a vaccine on vaccine recipients. However, vaccination is also known to bring about indirect benefits to a population through the reduction of virus circulation. The indirect effects of SARS-CoV-2 vaccination can play a key role in reducing case counts and COVID-19 deaths. To illustrate this point, we show through simulation that a vaccine with strong indirect effects has the potential to reduce SARS-CoV-2 circulation and COVID-19 deaths to a greater extent than an alternative vaccine with stronger direct effects but weaker indirect effects. Protection via indirect effects may be of particular importance in the context of this virus, because elderly individuals are at an elevated risk of death but are also less likely to be directly protected by vaccination due to immune senescence. We therefore encourage ongoing data collection and model development aimed at evaluating the indirect effects of forthcoming SARS-CoV-2 vaccines.


  • Open Access

    Causes and Consequences of Spatial Within-Host Viral Spread

    by Molly E. Gallagher, Christopher B. Brooke, Ruian Ke, Katia Koelle

    The spread of viral pathogens both between and within hosts is inherently a spatial process. While the spatial aspects of viral spread at the epidemiological level have been increasingly well characterized, the spatial aspects of viral spread within infected hosts are still understudied. Here, with a focus on influenza A viruses (IAVs), we first review experimental studies that have shed light on the mechanisms and spatial dynamics of viral spread within hosts. These studies provide strong empirical evidence for highly localized IAV spread within hosts. Since mathematical and computational within-host models have been increasingly used to gain a quantitative understanding of observed viral dynamic patterns, we then review the (relatively few) computational modeling studies that have shed light on possible factors that structure the dynamics of spatial within-host IAV spread. These factors include the dispersal distance of virions, the localization of the immune response, and heterogeneity in host cell phenotypes across the respiratory tract. While informative, we find in these studies a striking absence of theoretical expectations of how spatial dynamics may impact the dynamics of viral populations. To mitigate this, we turn to the extensive ecological and evolutionary literature on range expansions to provide informed theoretical expectations. We find that factors such as the type of density dependence, the frequency of long-distance dispersal, specific life history characteristics, and the extent of spatial heterogeneity are critical factors affecting the speed of population spread and the genetic composition of spatially expanding populations. For each factor that we identified in the theoretical literature, we draw parallels to its analog in viral populations. We end by discussing current knowledge gaps related to the spatial component of within-host IAV spread and the potential for within-host spatial considerations to inform the development of disease control strategies.